NCT05519410 is a Phase 2 clinical trial of Sintilimab and Lenvatinib in Resectable Hepatocellular Carcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital.

Who is sponsoring NCT05519410?

NCT05519410 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT05519410?

Interventions in NCT05519410: Sintilimab and Lenvatinib, HAIC-FOLFOX.

What condition does NCT05519410 study?

NCT05519410 studies Resectable Hepatocellular Carcinoma.

Is NCT05519410 still recruiting?

NCT05519410 is currently status unknown. Last updated 29 August 2022.

Last reviewed 2022-08-29 · How we verify

NCT05519410

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Status unknown Phase 2 Last updated 29 August 2022

What this trial tests

Phase 2 trial testing Sintilimab and Lenvatinib in Resectable Hepatocellular Carcinoma in 60 participants. Status unknown.

Timeline

23 August 2022

Primary endpoint
1 September 2024

1 September 2025

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	60
Start date	23 August 2022
Primary completion	1 September 2024
Estimated completion	1 September 2025
Sites	1 location across China

Drugs / interventions tested

Sintilimab and Lenvatinib — full drug profile →
HAIC-FOLFOX — full drug profile →

Conditions studied

Resectable Hepatocellular Carcinoma — all drugs for Resectable Hepatocellular Carcinoma →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

Adults 18 to 75, any sex, with Resectable Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, Two-arm, randomized，phase II clinical study of Sintilimab Combined With Lenvatinib Versus HAIC for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Small-molecule-based targeted therapy in liver cancer.
Ming Y, Gong Y, Fu X, Ouyang X, et al · · 2024 · cited 6× · PMID 39113358 · DOI 10.1016/j.ymthe.2024.08.001
Current Perspectives on Perioperative Combination Therapy for Hepatocellular Carcinoma.
Nishio T, Yoh T, Nishino H, Ogiso S, et al · · 2025 · cited 5× · PMID 40528897 · DOI 10.1159/000546138
Insights in Molecular Therapies for Hepatocellular Carcinoma.
Heumann P, Albert A, Gülow K, Tümen D, et al · · 2024 · cited 5× · PMID 38791911 · DOI 10.3390/cancers16101831
Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.
Koh B, Tan DJH, Lim WH, Wong JSL, et al · · 2023 · cited 4× · PMID 37284696 · DOI 10.1080/2162402x.2023.2214478
Current Immunotherapy Strategies and Emerging Biomarkers for the Treatment of Hepatocellular Carcinoma.
Kapelanski-Lamoureux A, Lazaris A, Meti N, Metrakos P. · · 2025 · PMID 41375071 · DOI 10.3390/cancers17233870

Verify or expand the search:

Other recruiting trials for Resectable Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06569498 — Neoadjuvant Triple Therapy for Resectable HCC · recruiting
NCT06524466 — Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma · Phase 2 · active not recruiting
NCT05701488 — SIRT With Tremelimumab and Durvalumab for Resectable HCC · Phase 1 · recruiting
NCT02379377 — 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant · Phase 1 · recruiting
NCT04856046 — Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer · active not recruiting

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05519410 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 29 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05519410.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing